Literature DB >> 27221555

[Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].

Joachim Labenz1, Gisela Labenz2, Dietmar Stephan3, Frank Willeke3.   

Abstract

BACKGROUND: Randomized controlled trials show that patients with gastroesophageal reflux disease (GERD) and treatment with proton pump inhibitors (PPI) in about 30% of the cases complain about persisting reflux symptoms (heartburn, regurgitation). The aim of the study was to evaluate the efficacy of PPI long-term treatment in patients with GERD in the family doctor's office.
METHOD: Patients with GERD and a PPI therapy of at least one year participated in a prospective, multicenter observational study. The patients obtained a questionnaire together with a further prescription of PPI. They were asked about the intensity and frequency of heartburn, regurgitation and sleep disorders due to reflux symptoms, satisfaction with PPI therapy, diagnostics performed up to now (endoscopy, pH monitoring, manometry) and surgical consultation. The questionnaire included a validated instrument for the diagnosis of GERD (GerdQ). Patients with the diagnosis "GERD " according to the questionnaire who were very dissatisfied with their current PPI therapy (score 1 or 2 on a 5-point Likert scale) were defined as "lost patients " (LOPA).
RESULTS: 39% of the patients still suffered from heartburn at least two days a week, 30% of regurgitation. In 22% of the patients, reflux symptoms led to sleep disorder at least two days a week. 20% of the patients were very dissatisfied with the current PPI therapy. 70% of them (= 14% of the total patient population) were "lost patients " according to the definition. An endoscopy was performed in 86% of the patients and function diagnosis (pH monitoring ± manometry) in 8%. A surgeon was consulted in 8% of the patients, a third of which had received function diagnosis before.
CONCLUSIONS: A poor symptom control can often be found in GERD patients with PPI long-term therapy, but does not stand out in the daily routine. So diagnosis will not continue and treatment alternatives will not be searched for. In the future quality of treatment should be verified e. g. by questionnaires.

Entities:  

Keywords:  gastroesophageal reflux disease (GERD); proton pump inhibitors (PPI); questionnaire; symptom control

Mesh:

Substances:

Year:  2016        PMID: 27221555     DOI: 10.1007/s15006-016-8303-0

Source DB:  PubMed          Journal:  MMW Fortschr Med        ISSN: 1438-3276


  5 in total

Review 1.  [Surgical and interventional procedures for reflux therapy : Endoscopic or laparoscopic?]

Authors:  K U Asche; A Kaindlstorfer; R Pointner
Journal:  Chirurg       Date:  2017-03       Impact factor: 0.955

2.  Pathophysiology of gastroesophageal reflux disease-which factors are important?

Authors:  Karl-Hermann Fuchs; Arielle M Lee; Wolfram Breithaupt; Gabor Varga; Benjamin Babic; Santiago Horgan
Journal:  Transl Gastroenterol Hepatol       Date:  2021-10-25

3.  Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease.

Authors:  Ya-Mei Zheng; Xian-Yun Chen; Jie-Yi Cai; Yu Yuan; Wen-Rui Xie; Jia-Ting Xu; Harry Hua-Xiang Xia; Min Zhang; Xing-Xiang He; Li-Hao Wu
Journal:  World J Gastroenterol       Date:  2021-02-14       Impact factor: 5.742

4.  Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study.

Authors:  Cathal Coyle; Russell Symonds; Jane Allan; Sarah Dawson; Sheldon Russell; Adam Smith; Colin Daff; Helen Kotze
Journal:  BJGP Open       Date:  2019-10-29

5.  Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Yasuhiko Gotoh; Emiko Ishibashi; Shunichiro Honda; Tomohisa Nakaya; Chishio Noguchi; Koichi Kagawa; Kazunari Murakami
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.